ABSTRACT
Transcranial near-infrared laser therapy (NILT) or low-level laser
(or light) therapy remains a promising noninvasive neuroprotective
method to treat acute ischemic stroke (AIS), despite the difficulties
observed with translation in clinical trials. Three clinical trials-
NeuroThera Effectiveness and Safety Trial (NEST)-1, NEST-2, and
NEST-3-have evaluated the use of NILT to promote clinical recovery
in patients with AIS; the results have been quite mixed. Can we
recover from this failure reminiscent of the SAINT clinical trial
failure?